| $687M | ||
| $385M | ||
| $215M | ||
| $100M | ||
| $87M | ||
| $82M |
Buys | $0 | 0 | 0 |
Sells | $24,884,966 | 9 | 100 |
| Norden Gregory | director | 0 | $0 | 1 | $1.21M | $-1.21M |
| Urist Marshall | EVP, Research & Investments | 0 | $0 | 2 | $3.29M | $-3.29M |
| Lloyd George W. | EVP, Investments & CLO | 0 | $0 | 2 | $9.57M | $-9.57M |
| Coyne Terrance P. | EVP & CFO | 0 | $0 | 4 | $10.82M | $-10.82M |
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Over the last 12 months, insiders at Royalty Pharma plc have bought $0 and sold $24.88M worth of Royalty Pharma plc stock.
On average, over the past 5 years, insiders at Royalty Pharma plc have bought $7.24M and sold $168.89M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 130,000 shares for transaction amount of $3.84M was made by Legorreta Pablo G. (CEO, Chairman of the Board) on 2023‑06‑28.
| 2025-12-05 | Sale | Urist Marshall | EVP, Research & Investments | 41,576 0.0094% | $39.15 | $1.63M | -1.83% | |
| 2025-12-03 | Sale | Lloyd George W. | EVP, Investments & CLO | 110,000 0.0254% | $39.77 | $4.38M | -3.47% | |
| 2025-12-01 | Sale | Coyne Terrance P. | EVP & CFO | 65,832 0.0152% | $39.87 | $2.62M | -3.28% | |
| 2025-12-01 | Sale | Coyne Terrance P. | EVP & CFO | 69,582 0.016% | $39.87 | $2.77M | -3.28% | |
| 2025-12-01 | Sale | Urist Marshall | EVP, Research & Investments | 41,575 0.0096% | $39.92 | $1.66M | -3.28% | |
| 2025-11-24 | Sale | Coyne Terrance P. | EVP & CFO | 69,582 0.0159% | $38.55 | $2.68M | -0.47% | |
| 2025-11-19 | Sale | Lloyd George W. | EVP, Investments & CLO | 135,426 0.0309% | $38.34 | $5.19M | +1.07% | |
| 2025-11-17 | Sale | Coyne Terrance P. | EVP & CFO | 69,594 0.0161% | $39.30 | $2.74M | -0.24% | |
| 2025-08-11 | Sale | Norden Gregory | director | 33,500 0.008% | $36.23 | $1.21M | +1.85% | |
| 2024-01-04 | Sale | RIGGS RORY B | director | 35,702 0.0083% | $27.55 | $983,504 | +1.67% | |
| 2024-01-03 | Sale | RIGGS RORY B | director | 199,098 0.0467% | $27.79 | $5.53M | +1.81% | |
| 2024-01-02 | Sale | RIGGS RORY B | director | 235,200 0.0566% | $28.52 | $6.71M | -0.13% | |
| 2023-12-29 | Sale | Avara Management Ltd | 10 percent owner | 65,803 0.0156% | $28.04 | $1.85M | +0.68% | |
| 2023-12-28 | Sale | Avara Management Ltd | 10 percent owner | 209,863 0.05% | $28.20 | $5.92M | +1.13% | |
| 2023-12-27 | Sale | Avara Management Ltd | 10 percent owner | 41,729 0.0099% | $28.01 | $1.17M | +0.92% | |
| 2023-12-15 | Sale | Avara Management Ltd | 10 percent owner | 10,229 0.0024% | $28.01 | $286,499 | +3.32% | |
| 2023-12-14 | Sale | Avara Management Ltd | 10 percent owner | 364,441 0.0889% | $28.91 | $10.53M | -1.25% | |
| 2023-12-13 | Sale | Avara Management Ltd | 10 percent owner | 307,935 0.0753% | $28.95 | $8.92M | -3.22% | |
| 2023-08-10 | Sale | Coyne Terrance P. | EVP & CFO | 37,500 0.0097% | $30.75 | $1.15M | -6.42% | |
| 2023-08-09 | Sale | Coyne Terrance P. | EVP & CFO | 37,500 0.0097% | $30.72 | $1.15M | -6.25% |
| Norden Gregory | director | 194848 0.0449% | $7.48M | 0 | 1 | |
| Lloyd George W. | EVP, Investments & CLO | 110000 0.0253% | $4.22M | 1 | 36 | <0.0001% |
| Coyne Terrance P. | EVP & CFO | 47260 0.0109% | $1.81M | 1 | 13 | <0.0001% |
| Urist Marshall | EVP, Research & Investments | 7398 0.0017% | $283,935.24 | 0 | 11 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 10 percent owner | 38714280 8.9181% | $1.49B | 1 | 2 | <0.0001% |
| GG 1978 SICAF SIF S.A. | 22081156 5.0865% | $847.47M | 0 | 4 | ||
| GG 1978 SICAF SIF S.A. - GG Strategic | 21426170 4.9356% | $822.34M | 0 | 3 | ||
| Giuliani Mario Germano | director | 7795072 1.7956% | $299.17M | 1 | 10 | <0.0001% |
| Lappe Mark | 4292136 0.9887% | $164.73M | 10 | 0 | ||
| PERCEPTIVE ADVISORS LLC | 10 percent owner | 2862560 0.6594% | $109.87M | 14 | 3 | |
| Efficacy Capital, Ltd. | 10 percent owner | 2552233 0.5879% | $97.95M | 36 | 20 | |
| Avara Management Ltd | 10 percent owner | 2477520 0.5707% | $95.09M | 0 | 9 | |
| FORD WILLIAM E | director | 1500000 0.3455% | $57.57M | 1 | 0 | <0.0001% |
| Reddoch James F. | EVP & Chief Scientific Officer | 820800 0.1891% | $31.5M | 0 | 19 | |
| Legorreta Pablo G. | CEO, Chairman of the Board | 600000 0.1382% | $23.03M | 7 | 0 | <0.0001% |
| Fernandez Henry A | director | 58200 0.0134% | $2.23M | 2 | 0 | <0.0001% |
| Hite Christopher | EVP & Vice Chairman | 30541 0.007% | $1.17M | 1 | 1 | <0.0001% |
| RIGGS RORY B | director | 20099 0.0046% | $771,399.62 | 1 | 28 | <0.0001% |
| REED JOHN C | director | 3846 0.0009% | $147,609.48 | 1 | 0 | |
| Masterson Nola E | director | 0 0% | $0 | 6 | 1 |
$961,890,236 | 276 | 22.46% | $19.05B | |
$211,610,344 | 91 | 38.45% | $12.3B | |
$2,765,836 | 72 | 20.00% | $9.95B | |
$2,449,191,716 | 58 | 16.50% | $77.09B | |
$11,789,714 | 49 | 14.35% | $42.8B | |
$323,530,732 | 48 | 29.90% | $51.68B | |
$88,307,390 | 38 | -1.70% | $10.31B | |
$19,233,721 | 36 | 70.14% | $11.15B | |
$13,655,378 | 35 | 17.13% | $22.34B | |
$15,836,193 | 25 | 17.98% | $116.75B | |
$415,090,639 | 19 | -14.04% | $14.42B | |
$143,065,458 | 17 | 8.01% | $14.99B | |
Royalty Pharma plc (RPRX) | $152,272,932 | 16 | -10.78% | $16.66B |
$627,701,115 | 15 | 145.68% | $12.83B | |
$103,741 | 9 | 49.60% | $12.45B | |
$948,235 | 8 | 15.56% | $9B | |
$40,276,273 | 4 | 34.57% | $15.95B | |
$36,900,000 | 3 | -9.12% | $9.45B | |
$999,989 | 1 | 262.16% | $11.68B |
| Increased Positions | 309 | +71.03% | 45M | +13.14% |
| Decreased Positions | 189 | -43.45% | 55M | -15.9% |
| New Positions | 94 | New | 10M | New |
| Sold Out Positions | 54 | Sold Out | 7M | Sold Out |
| Total Postitions | 555 | +27.59% | 334M | -2.76% |
| Morgan Stanley | $1.7M | 10.34% | 44.16M | -2M | -5.24% | 2025-09-30 |
| Fmr Llc | $1.07M | 6.55% | 27.99M | -12M | -30.65% | 2025-09-30 |
| Capital International Investors | $1.04M | 6.37% | 27.21M | +5M | +24.37% | 2025-09-30 |
| Blackrock, Inc. | $1.01M | 6.14% | 26.2M | +771,647 | +3.04% | 2025-09-30 |
| Baillie Gifford & Co | $666,930.00 | 4.07% | 17.37M | -647,953 | -3.6% | 2025-09-30 |
| Swedbank Ab | $468,368.00 | 2.86% | 12.2M | +42,800 | +0.35% | 2025-09-30 |
| Adage Capital Partners Gp, L.L.C. | $459,361.00 | 2.8% | 11.97M | +6M | +99.43% | 2025-09-30 |
| Vanguard Group Inc | $419,854.00 | 2.56% | 10.94M | -25M | -69.94% | 2025-09-30 |
| State Street Corp | $394,371.00 | 2.41% | 10.27M | +77,815 | +0.76% | 2025-09-30 |
| Geode Capital Management, Llc | $292,432.00 | 1.78% | 7.62M | -559,091 | -6.84% | 2025-09-30 |